Botanical Medicines for the Treatment of Cancer: Rationale, Overview of Current Data, and Methodological Considerations for Phase I and II Trials
- 1 January 2002
- journal article
- review article
- Published by Taylor & Francis Ltd in Cancer Investigation
- Vol. 20 (7-8), 1069-1079
- https://doi.org/10.1081/cnv-120005926
Abstract
There appears to be exceptional and growing public enthusiasm for botanical, or “herbal”, medicines, especially amongst cancer patients. This has recently begun to be matched by increasing scientific attention. Whilst it is known that plant extracts are active against cancer, the standard approach has been to isolate, synthesize and administer the single chemical compound thought responsible for this effect. However, different components in a botanical may have synergistic activities. There is also some evidence that the presence of multiple compounds in a botanical extract can buffer the toxic effects of a single constituent. Though many of the botanicals popular among patients are probably not of benefit (e.g. Mistletoe, Pau D'arco), several botanicals have shown promise in Phase III (Sho-saiko-to, PSK) or Phase II (PC-SPES) trial. Quality control of botanicals poses significant challenges: small differences in genetics, soil, temperature, moisture and time of harvesting can lead to significant differences in the concentration of important constituents. Phase I and II methodology is also problematic: botanicals have low toxicity and are unlikely to cause rapid tumor regression. There is currently minimal regulation of botanical medicines.Keywords
This publication has 63 references indexed in Scilit:
- Huanglian, A Chinese Herbal Extract, Inhibits Cell Growth by Suppressing the Expression of Cyclin B1 and Inhibiting CDC2 Kinase Activity in Human Cancer CellsMolecular Pharmacology, 2000
- Indinavir concentrations and St John's wortThe Lancet, 2000
- ABC of complementary medicine: Herbal medicineBMJ, 1999
- Trends in Alternative Medicine Use in the United States, 1990-1997Jama-Journal Of The American Medical Association, 1998
- Herbal MedicinalsArchives of Internal Medicine, 1998
- Use of Fingerprinting and Marker Compounds for Identification and Standardization of Botanical Drugs: Strategies for Applying Pharmaceutical HPLC Analysis to Herbal ProductsDrug Information Journal, 1998
- Augmentation of NK Activity after Oral Administration of a Traditional Chinese Medicine, Xiao-Chai-Hu-Tang (Shosaiko-To)Immunopharmacology and Immunotoxicology, 1994
- Anti-growth effects with components of Sho-saiko-to (TJ-9) on cultured human hepatoma cellsEuropean Journal of Cancer Prevention, 1993
- Effects of a Blended Chinese Medicine, Xiao-Chai-Hu-Tang, on Lewis Lung Carcinoma Growth and Inhibition of Lung Metastasis, with Special Reference to Macrophage ActivationThe Japanese Journal of Pharmacology, 1986
- Inhibition of sensitization reactions induced by certain aldehydesFood and Cosmetics Toxicology, 1976